Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report details a specific corporate action regarding a share repurchase executed on February 22, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 525,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,193.5 pence per share; lowest price paid was 1,176.0 pence per share.
- Treasury Holdings (Settled): 482,762,284 shares (8.51% of total issued share capital).
- Treasury Holdings (Including Unsettled): 483,704,284 shares (9.32% of total voting rights).
- Shares in Issue: 5,188,072,606 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 525,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.32% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,188,072,606) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (9.32% including unsettled shares).
- Review the specific price range paid (1,176.0 to 1,193.5 pence) for the February 22, 2011 transaction.